首页> 外文期刊>Oncology reports >RUNX2 promotes hepatocellular carcinoma cell migration and invasion by upregulating MMP9 expression
【24h】

RUNX2 promotes hepatocellular carcinoma cell migration and invasion by upregulating MMP9 expression

机译:RUNX2通过上调MMP9表达来促进肝癌细胞的迁移和侵袭

获取原文
获取原文并翻译 | 示例
           

摘要

Runt-related transcription factor 2 (RUNX2) was first identified as a transcription factor to play an important role in different biological processes of osteoblast and chondrocyte, including differentiation and migration. Recently, RUNX2 has been implicated in promigratory/proinvasive behavior in different human malignancies. In the present study, we demonstrated that the RUNX2 mRNA and protein expression were both increased significantly in HCC tissues and cell lines. High RUNX2 expression was correlated obviously with poor clinicopathological characteristics including multiple tumor nodes, high histological grading, venous infiltration and advanced tumor-node-metastasis (TNM) stage. In addition, we demonstrated that RUNX2 was a prognostic indicator for predicting 5-year overall survival and disease-free survival of HCC patients. Our studies showed that RUXN2 overexpression promoted, while RUNX2 knockdown inhibited HCC cell migration and invasion in vitro. Notably, RUNX2 positively regulated matrix metalloproteinase 9 (MMP9) accumulation in HCC cells. Furthermore, we confirmed that RUNX2 was positively correlated with MMP9 expression in HCC tissues by Pearson correlation analysis. Mechanistically, we demonstrated that MMP9 overexpression increased HCC cell migration and invasion, while MMP9 knockdown reduced HCC cell migration and invasion in vitro. Alteration of MMP9 expression partially abrogated the effects of RUNX2 on HCC cell migration and invasion, which suggests that RUNX2 developed its pro-metastatic biological function by upregulating the expression of MMP9 in HCC cells. In conclusion, our results reveal that RUNX2 promotes HCC cell migration and invasion by MMP9-mediated pathway, and potentially serves as a new prognostic biomarker and in therapeutic strategies for HCC.
机译:矮小相关转录因子2(RUNX2)首先被鉴定为在成骨细胞和软骨细胞的不同生物学过程(包括分化和迁移)中起重要作用的转录因子。最近,RUNX2与不同人类恶性肿瘤的侵袭/侵袭行为有关。在本研究中,我们证明了RUNX2 mRNA和蛋白表达在HCC组织和细胞系中均显着增加。 RUNX2高表达与不良的临床病理特征明显相关,包括多个肿瘤淋巴结,高组织学分级,静脉浸润和晚期肿瘤淋巴结转移(TNM)阶段。此外,我们证明RUNX2是预测HCC患者5年总生存期和无病生存期的预后指标。我们的研究表明,RUXN2的过度表达得到促进,而RUNX2的敲低则抑制了HCC细胞在体外的迁移和侵袭。值得注意的是,RUNX2在HCC细胞中正调控基质金属蛋白酶9(MMP9)的积累。此外,我们通过皮尔逊相关分析证实了RUNX2与HCC组织中MMP9的表达呈正相关。从机制上讲,我们证明了MMP9的过表达增加了HCC细胞的迁移和侵袭,而MMP9的敲低降低了HCC的细胞迁移和侵袭。 MMP9表达的改变部分地消除了RUNX2对HCC细胞迁移和侵袭的影响,这表明RUNX2通过上调HCC细胞中MMP9的表达来发展其转移前的生物学功能。总之,我们的结果表明,RUNX2通过MMP9介导的途径促进HCC细胞迁移和侵袭,并有可能作为HCC的新的预后生物标志物和治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号